Afatinib in NSCLC with uncommon EGFR mutations

Written by James Chih-Hsin Yang

The latest Publication Perspective from the Video Journal of Biomedicine summarizes a recent article published in the Journal of Thoracic Oncology, ‘Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Database of 693 Cases’.

The authors analyze the effect of afatinib treatment in 693 patients with non-small-cell lung cancer (NSCLC) haboring uncommon EGFR mutations. The results provide important information when considering optimal treatment for tumors with uncommon EGFR mutations, including compound mutations.

Original publication:

Yang JCH, Schuler M, Popat S et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: A database of 693 cases. J. Thorac. Oncol. 15(5), 803–815 (2020) DOI: 10.1016/j.jtho.2019.12.126

About the Video Journal of Biomedicine:

The Video Journal of Biomedicine, published by Future Medicine, provides the missing link between high-quality research information and its intended audience, be that fellow experts, researchers in other fields, students and trainees, or the general public (including patients and caregivers). Through concise, high-quality videos, with the author on screen or via voice-over animation, researchers are able to personally explain their work, highlighting its importance, placing it in context, and discussing future implications.

Visit the Video Journal of Biomedicine to find out more>>

The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Oncology Central or Future Science Group.